{"disease":{"id":"myeloproliferative-neoplasms-mpn","name":"myeloproliferative neoplasms mpn"},"drugs":{"marketed":[{"drug_id":"part-c-met097","indication_name":"Treatment of Myeloproliferative Neoplasms (MPNs)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT06740916","title":"Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT02393248","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":201,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT07384039","title":"Exercise Training in Patients With Myeloproliferative Neoplasms","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Hannover Medical School","has_results":false},{"nct_id":"NCT06753279","title":"Clinical Significance of Leukocyte Cell Population Data in Patients With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04113616","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05782985","title":"Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs","phase":"","overall_status":"UNKNOWN","enrollment_count":52,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT01393509","title":"The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}